The scariest thing about gray-market peptides is how little we know
Key Takeaways
- Gray-market peptides lack official clinical trials and concrete safety data.
- Users often experiment with substances like BPC-157 without medical oversight.
- Many consumers delay disclosing their peptide usage to doctors for months.
The growing trend of gray-market peptides represents a significant blind spot in modern health and wellness. With little to no official clinical data available, consumers are essentially navigating a wild west of unregulated substances.
Compounding the issue, research shows that individuals using these peptides often delay telling their doctors for months, or keep it a secret altogether, increasing potential health risks.
Recommended for you
Tools and services we trust to boost productivity and content workflows.
Browse picks